Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)

by Masucci, Lisa, Beca, Jaclyn, Sabharwal, Mona, Hoch, Jeffrey S.
Published 2017

Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?

by Hoch, Jeffrey S., Beca, Jaclyn, Sabharwal, Mona, Livingstone, Scott W., Fields, Anthony L. A.
Published 2015

Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: a simulation study

by Beca, Jaclyn M., Chan, Kelvin K. W., Naimark, David M. J., Pechlivanoglou, Petros
Published 2021

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma

by Habbous, Steven, Guo, Helen, Beca, Jaclyn, Dai, Wei Fang, Isaranuwatchai, Wanrudee, Cheung, Matthew, Chan, Kelvin K. W.
Published 2020

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada

by Beca, Jaclyn M., Walsh, Shaun, Raza, Kaiwan, Hubay, Stacey, Robinson, Andrew, Mow, Elena, Keech, James, Chan, Kelvin K. W.
Published 2021

Improving chronic disease prevention and screening in primary care: results of the BETTER pragmatic cluster randomized controlled trial

by Grunfeld, Eva, Manca, Donna, Moineddin, Rahim, Thorpe, Kevin E, Hoch, Jeffrey S, Campbell-Scherer, Denise, Meaney, Christopher, Rogers, Jess, Beca, Jaclyn, Krueger, Paul, Mamdani, Muhammad
Published 2013

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer

by Dai, Wei Fang, Beca, Jaclyn M., Nagamuthu, Chenthila, Liu, Ning, de Oliveira, Claire, Earle, Craig C., Trudeau, Maureen, Mercer, Rebecca E., Chan, Kelvin K. W.
Published 2022

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

by Chan, Kelvin, Nam, Seungree, Evans, Bill, de Oliveira, Claire, Chambers, Alexandra, Gavura, Scott, Hoch, Jeffrey, Mercer, Rebecca E, Dai, Wei Fang, Beca, Jaclyn, Tadrous, Mina, Isaranuwatchai, Wanrudee
Published 2020

Are population‐based patient‐reported outcomes associated with overall survival in patients with advanced pancreatic cancer?

by Dai, Wei Fang, Beca, Jaclyn, Guo, Helen, Isaranawatchai, Wanrudee, Schwartz, Deborah, Naipaul, Rohini, Arias, Jessica, Qiao, Yao, Gavura, Scott, Redmond‐Misner, Ruby, Ismail, Zahra, Barbera, Lisa, Chan, Kelvin
Published 2019

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada

by Dai, Wei Fang, Beca, Jaclyn M., Croxford, Ruth, Isaranawatchai, Wanrudee, Menjak, Ines B., Petrella, Teresa M., Mittmann, Nicole, Earle, Craig C., Gavura, Scott, Hanna, Timothy P., Chan, Kelvin K.W.
Published 2020

Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies i...

by Pataky, Reka E., Beca, Jaclyn, Tran, David, Dai, Wei Fang, Dvorani, Erind, Isaranuwatchai, Wanrudee, Peacock, Stuart, Alvi, Riaz, Cheung, Winson Y., Earle, Craig C., Gavura, Scott, Chan, Kelvin K. W.
Published 2021

The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer

by Raphael, Michael J., Raskin, William, Habbous, Steven, Tai, Xiaochen, Beca, Jaclyn, Dai, Wei F., Arias, Jessica, Forbes, Leta, Gavura, Scott, Biagi, James J., Earle, Craig C., Chan, Kelvin K. W.
Published 2021

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization

by Lu, Brandon, Dai, Wei Fang, Croxford, Ruth, Isaranuwatchai, Wanrudee, Beca, Jaclyn, Menjak, Ines B., Petrella, Teresa M., Mittmann, Nicole, Earle, Craig C., Gavura, Scott, Mercer, Rebecca E., Hanna, Timothy P., Chan, Kelvin K. W.
Published 2023

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis

by Khor, Sara, Beca, Jaclyn, Krahn, Murray, Hodgson, David, Lee, Linda, Crump, Michael, Bremner, Karen E, Luo, Jin, Mamdani, Muhammad, Bell, Chaim M, Sawka, Carol, Gavura, Scott, Sullivan, Terrence, Trudeau, Maureen, Peacock, Stuart, Hoch, Jeffrey S
Published 2014

Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer

by Arciero, Vanessa, Luo, Jin, Parmar, Ambica, Dai, Wei Fang, Beca, Jaclyn M, Raphael, Michael J, Isaranuwatchai, Wanrudee, Habbous, Steven, Tadrous, Mina, Earle, Craig C, Biagi, Jim J, Mittmann, Nicole, Arias, Jessica, Gavura, Scott, Chan, Kelvin K W
Published 2022

Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simu...

by Dai, Wei Fang, Craig, Erica, Fraser, Brent, Chambers, Alex, Mai, Helen, Brown, M. Bryson, Earle, Craig C., Evans, William K., Geirnaert, Marc, Taylor, Marianne, Trudeau, Maureen, Sperber, Daniel, Beca, Jaclyn M., Denburg, Avram, Mercer, Rebecca E., Parmar, Ambica, Tadrous, Mina, Takhar, Pam, Chan, Kelvin K. W.
Published 2021

Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Wo...

by Dai, Wei Fang, Arciero, Vanessa, Craig, Erica, Fraser, Brent, Arias, Jessica, Boehm, Darryl, Bosnic, Nevzeta, Caetano, Patricia, Chambers, Carole, Jones, Barry, Lungu, Elena, Mitera, Gunita, Potashnik, Tanya, Reiman, Anthony, Ritcher, Trevor, Beca, Jaclyn M., Denburg, Avram, Mercer, Rebecca E., Parmar, Ambica, Tadrous, Mina, Takhar, Pam, Chan, Kelvin K. W.
Published 2021

Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis

by Chan, Kelvin K. W., Guo, Helen, Cheng, Sierra, Beca, Jaclyn M., Redmond‐Misner, Ruby, Isaranuwatchai, Wanrudee, Qiao, Lucy, Earle, Craig, Berry, Scott R., Biagi, James J., Welch, Stephen, Meyers, Brandon M., Mittmann, Nicole, Coburn, Natalie, Arias, Jessica, Schwartz, Deborah, Dai, Wei F., Gavura, Scott, McLeod, Robin, Kennedy, Erin D.
Published 2019

Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada

by Habbous, Steven, Tai, Xiaochen, Beca, Jaclyn M, Arias, Jessica, Raphael, Michael J., Parmar, Ambica, Crespo, Andrea, Cheung, Matthew C, Eisen, Andrea, Eskander, Antoine, Singh, Simron, Trudeau, Maureen, Gavura, Scott, Dai, Wei Fang, Irish, Jonathan, Krzyzanowska, Monika, Lapointe-Shaw, Lauren, Naipaul, Rohini, Peacock, Stuart, Yeung, Lyndee, Forbes, Leta, Chan, Kelvin K. W.
Published 2022

Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue...

by Parmar, Ambica, Dai, Wei Fang, Dionne, Francois, Geirnaert, Marc, Denburg, Avram, Ahuja, Tarry, Beca, Jaclyn, Bouchard, Sylvie, Chambers, Carole, Hunt, Melissa J., Husereau, Don, Lungu, Elena, McDonald, Valerie, Mercer, Rebecca E., Mitera, Gunita, Muñoz, Caroline, Naipaul, Rohini, Peacock, Stuart, Potashnik, Tanya, Tadrous, Mina, Takhar, Pam, Taylor, Marianne, Trudeau, Maureen, Wasney, Danica, Gavura, Scott, Chan, Kelvin K. W.
Published 2023